|
MechanismSARS-CoV-2 N protein inhibitors [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with MigVax
0 Patents (Medical) associated with MigVax
100 Deals associated with MigVax
100 Translational Medicine associated with MigVax